NO324693B1 - 2-acetamidoacetamidderivater, anvendelse av slike forbindelser til fremstilling av preparater for behandling av sykdommer samt preparater omfattende slike forbindelser - Google Patents

2-acetamidoacetamidderivater, anvendelse av slike forbindelser til fremstilling av preparater for behandling av sykdommer samt preparater omfattende slike forbindelser Download PDF

Info

Publication number: NO324693B1
Authority: NO; Norway
Prior art keywords: alkyl; phenyl; group; substituted; methyl
Prior art date: 2000-05-12

Application number

NO20025405A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025405D0 (no

NO20025405L (no

Inventor

Scott F Sneddon

John L Kane

Bradford H Hirth

Fred Vinick

Shuang Qiao

Sharon R Nahill

John M Williams

Hans-Peter Biemann

Andrew Janjigian

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-12

Filing date

2002-11-11

Publication date

2007-12-03

2002-11-11 Application filed by Genzyme Corp filed Critical Genzyme Corp

2002-11-11 Publication of NO20025405D0 publication Critical patent/NO20025405D0/no

2003-01-09 Publication of NO20025405L publication Critical patent/NO20025405L/no

2007-12-03 Publication of NO324693B1 publication Critical patent/NO324693B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 103
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 54
238000002360 preparation method Methods 0.000 title claims description 37
239000000203 mixture Substances 0.000 title claims description 24
201000010099 disease Diseases 0.000 title claims description 9
WQELDIQOHGAHEM-UHFFFAOYSA-N 2-acetamidoacetamide Chemical class CC(=O)NCC(N)=O WQELDIQOHGAHEM-UHFFFAOYSA-N 0.000 title 1
-1 benzophenoyl Chemical group 0.000 claims description 250
125000000217 alkyl group Chemical group 0.000 claims description 102
125000003118 aryl group Chemical group 0.000 claims description 69
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 68
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 68
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 65
208000035475 disorder Diseases 0.000 claims description 45
125000001072 heteroaryl group Chemical group 0.000 claims description 41
125000003710 aryl alkyl group Chemical group 0.000 claims description 36
230000001404 mediated effect Effects 0.000 claims description 31
125000000753 cycloalkyl group Chemical group 0.000 claims description 27
125000004475 heteroaralkyl group Chemical group 0.000 claims description 26
125000001424 substituent group Chemical group 0.000 claims description 22
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 18
150000008378 aryl ethers Chemical group 0.000 claims description 17
229910052736 halogen Inorganic materials 0.000 claims description 16
150000002367 halogens Chemical class 0.000 claims description 16
230000001684 chronic effect Effects 0.000 claims description 15
125000004093 cyano group Chemical group *C#N 0.000 claims description 15
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 15
125000003226 pyrazolyl group Chemical group 0.000 claims description 14
239000000825 pharmaceutical preparation Substances 0.000 claims description 13
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
230000007170 pathology Effects 0.000 claims description 12
125000004076 pyridyl group Chemical group 0.000 claims description 12
125000001624 naphthyl group Chemical group 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
125000000623 heterocyclic group Chemical group 0.000 claims description 10
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000000168 pyrrolyl group Chemical group 0.000 claims description 9
125000001544 thienyl group Chemical group 0.000 claims description 9
230000001154 acute effect Effects 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims description 8
125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 7
125000004122 cyclic group Chemical group 0.000 claims description 7
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 7
125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 7
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 6
125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 6
230000007850 degeneration Effects 0.000 claims description 6
125000001041 indolyl group Chemical group 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 5
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 5
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 5
239000012965 benzophenone Chemical group 0.000 claims description 5
125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 5
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 5
125000002883 imidazolyl group Chemical group 0.000 claims description 5
125000005945 imidazopyridyl group Chemical group 0.000 claims description 5
125000005956 isoquinolyl group Chemical group 0.000 claims description 5
125000001786 isothiazolyl group Chemical group 0.000 claims description 5
125000000842 isoxazolyl group Chemical group 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
125000002971 oxazolyl group Chemical group 0.000 claims description 5
125000005936 piperidyl group Chemical group 0.000 claims description 5
125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
125000005493 quinolyl group Chemical group 0.000 claims description 5
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 5
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
125000005888 tetrahydroindolyl group Chemical group 0.000 claims description 5
125000003831 tetrazolyl group Chemical group 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 4
206010003591 Ataxia Diseases 0.000 claims description 4
208000015879 Cerebellar disease Diseases 0.000 claims description 4
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
208000016285 Movement disease Diseases 0.000 claims description 4
208000018254 acute transverse myelitis Diseases 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
230000003902 lesion Effects 0.000 claims description 4
125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
208000009174 transverse myelitis Diseases 0.000 claims description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 3
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims description 3
125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims description 3
125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims description 3
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 3
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 claims description 3
125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 claims description 3
125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 3
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 3
125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 3
125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 3
208000035143 Bacterial infection Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
206010025323 Lymphomas Diseases 0.000 claims description 3
208000022362 bacterial infectious disease Diseases 0.000 claims description 3
230000002490 cerebral effect Effects 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
208000007848 Alcoholism Diseases 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims description 2
208000023328 Basedow disease Diseases 0.000 claims description 2
206010008748 Chorea Diseases 0.000 claims description 2
206010009193 Circulatory collapse and shock Diseases 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
208000024412 Friedreich ataxia Diseases 0.000 claims description 2
208000015023 Graves' disease Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
208000000269 Hyperkinesis Diseases 0.000 claims description 2
208000006264 Korsakoff syndrome Diseases 0.000 claims description 2
208000009829 Lewy Body Disease Diseases 0.000 claims description 2
201000002832 Lewy body dementia Diseases 0.000 claims description 2
208000005587 Refsum Disease Diseases 0.000 claims description 2
206010039710 Scleroderma Diseases 0.000 claims description 2
206010053879 Sepsis syndrome Diseases 0.000 claims description 2
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
206010043189 Telangiectasia Diseases 0.000 claims description 2
206010044688 Trisomy 21 Diseases 0.000 claims description 2
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 2
208000030597 adult Refsum disease Diseases 0.000 claims description 2
230000001363 autoimmune Effects 0.000 claims description 2
230000001580 bacterial effect Effects 0.000 claims description 2
210000004227 basal ganglia Anatomy 0.000 claims description 2
208000018300 basal ganglia disease Diseases 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
210000001638 cerebellum Anatomy 0.000 claims description 2
230000001054 cortical effect Effects 0.000 claims description 2
230000002594 corticospinal effect Effects 0.000 claims description 2
208000017004 dementia pugilistica Diseases 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
208000006454 hepatitis Diseases 0.000 claims description 2
231100000283 hepatitis Toxicity 0.000 claims description 2
230000003483 hypokinetic effect Effects 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims description 2
230000002438 mitochondrial effect Effects 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
201000000585 muscular atrophy Diseases 0.000 claims description 2
230000004770 neurodegeneration Effects 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
230000003071 parasitic effect Effects 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
201000000306 sarcoidosis Diseases 0.000 claims description 2
230000003248 secreting effect Effects 0.000 claims description 2
208000009056 telangiectasis Diseases 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
230000003612 virological effect Effects 0.000 claims description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
208000009329 Graft vs Host Disease Diseases 0.000 claims 1
201000006704 Ulcerative Colitis Diseases 0.000 claims 1
125000003158 alcohol group Chemical group 0.000 claims 1
208000024386 fungal infectious disease Diseases 0.000 claims 1
208000024908 graft versus host disease Diseases 0.000 claims 1
201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
239000000243 solution Substances 0.000 description 40
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
239000000047 product Substances 0.000 description 25
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
238000000034 method Methods 0.000 description 18
238000005481 NMR spectroscopy Methods 0.000 description 15
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 15
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
229910052938 sodium sulfate Inorganic materials 0.000 description 14
235000011152 sodium sulphate Nutrition 0.000 description 14
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
230000000694 effects Effects 0.000 description 13
239000012044 organic layer Substances 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 12
235000017557 sodium bicarbonate Nutrition 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
230000011664 signaling Effects 0.000 description 9
239000000377 silicon dioxide Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
239000006260 foam Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 7
239000000654 additive Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
238000010992 reflux Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
238000006058 Ugi-reaction Methods 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000007858 starting material Substances 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
125000000392 cycloalkenyl group Chemical group 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
231100000682 maximum tolerated dose Toxicity 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
FGTYTUFKXYPTML-UHFFFAOYSA-N 2-benzoylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 FGTYTUFKXYPTML-UHFFFAOYSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
206010040047 Sepsis Diseases 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
108700012920 TNF Proteins 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
235000011114 ammonium hydroxide Nutrition 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
239000004305 biphenyl Substances 0.000 description 3
235000010290 biphenyl Nutrition 0.000 description 3
125000006267 biphenyl group Chemical group 0.000 description 3
125000002837 carbocyclic group Chemical group 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
239000000470 constituent Substances 0.000 description 3
239000012043 crude product Substances 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
238000013537 high throughput screening Methods 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
125000001183 hydrocarbyl group Chemical group 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
150000003141 primary amines Chemical class 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
208000011580 syndromic disease Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
IGNLHPWFKZHBCW-UHFFFAOYSA-N (4-pyridin-2-ylpyrimidin-2-yl)hydrazine Chemical compound NNC1=NC=CC(C=2N=CC=CC=2)=N1 IGNLHPWFKZHBCW-UHFFFAOYSA-N 0.000 description 2
RXMTUVIKZRXSSM-UHFFFAOYSA-N 2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CN)C1=CC=CC=C1 RXMTUVIKZRXSSM-UHFFFAOYSA-N 0.000 description 2
OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 2
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
NXAKCKIAIOTNFA-UHFFFAOYSA-N 2-methylsulfanyl-4-pyridin-2-ylpyrimidine Chemical compound CSC1=NC=CC(C=2N=CC=CC=2)=N1 NXAKCKIAIOTNFA-UHFFFAOYSA-N 0.000 description 2
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000004296 chiral HPLC Methods 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940125898 compound 5 Drugs 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000002024 ethyl acetate extract Substances 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
238000012545 processing Methods 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
238000003756 stirring Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
JIPPKVDKFJRSEG-UHFFFAOYSA-N (2-isocyano-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(C[N+]#[C-])C1=CC=CC=C1 JIPPKVDKFJRSEG-UHFFFAOYSA-N 0.000 description 1
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
BWERGHWJEBQNQV-SOFGYWHQSA-N (e)-3-(dimethylamino)-1-pyridin-2-ylprop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CC=CC=N1 BWERGHWJEBQNQV-SOFGYWHQSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
PGCGACBWMXEHHA-UHFFFAOYSA-N 2-(1-tritylimidazol-4-yl)ethanol Chemical compound C1=NC(CCO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PGCGACBWMXEHHA-UHFFFAOYSA-N 0.000 description 1
MAUPYODWFFWAEZ-UHFFFAOYSA-N 2-(2,2-dimethylpropanoyl)benzoic acid Chemical compound CC(C)(C)C(=O)C1=CC=CC=C1C(O)=O MAUPYODWFFWAEZ-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
ZNGRLTWUVOPRQX-UHFFFAOYSA-N 2-benzoyl-n-[2-(2,2-diphenylethylamino)-2-oxo-1-phenylethyl]-n-[2-(1h-imidazol-5-yl)ethyl]benzamide Chemical compound C=1NC=NC=1CCN(C(=O)C=1C(=CC=CC=1)C(=O)C=1C=CC=CC=1)C(C=1C=CC=CC=1)C(=O)NCC(C=1C=CC=CC=1)C1=CC=CC=C1 ZNGRLTWUVOPRQX-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HGZJJKZPPMFIBU-UHFFFAOYSA-N 3-formylbenzonitrile Chemical compound O=CC1=CC=CC(C#N)=C1 HGZJJKZPPMFIBU-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
QEWVMYQGRIZDCX-UHFFFAOYSA-N CC(=O)[ClH]C(=O)C(O)C1=CC=CC=C1 Chemical compound CC(=O)[ClH]C(=O)C(O)C1=CC=CC=C1 QEWVMYQGRIZDCX-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010048748 Graft loss Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
238000006751 Mitsunobu reaction Methods 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
WLKNCSXSKQLIFG-UHFFFAOYSA-N N1C=NC=C1CCC1=C(C(=O)N)C=CC=C1 Chemical compound N1C=NC=C1CCC1=C(C(=O)N)C=CC=C1 WLKNCSXSKQLIFG-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000016202 Proteolipids Human genes 0.000 description 1
108010010974 Proteolipids Proteins 0.000 description 1
208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
208000011641 Spinocerebellar disease Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
125000006242 amine protecting group Chemical group 0.000 description 1
GRKUXCWELVWVMZ-UHFFFAOYSA-N amino acetate Chemical compound CC(=O)ON GRKUXCWELVWVMZ-UHFFFAOYSA-N 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
210000002226 anterior horn cell Anatomy 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940125844 compound 46 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000014793 distal colitis Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
150000002527 isonitriles Chemical class 0.000 description 1
201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
201000005962 mycosis fungoides Diseases 0.000 description 1
UWYDKXDDCSKCOV-UHFFFAOYSA-N n-(2,2-diphenylethyl)-2-[2-(1h-imidazol-5-yl)ethylamino]-n-methyl-2-phenylacetamide Chemical compound C=1NC=NC=1CCNC(C=1C=CC=CC=1)C(=O)N(C)CC(C=1C=CC=CC=1)C1=CC=CC=C1 UWYDKXDDCSKCOV-UHFFFAOYSA-N 0.000 description 1
ORJRZRKDHRCATL-UHFFFAOYSA-N n-(2,2-diphenylethyl)-2-hydroxy-n-methyl-2-phenylacetamide Chemical compound C=1C=CC=CC=1C(O)C(=O)N(C)CC(C=1C=CC=CC=1)C1=CC=CC=C1 ORJRZRKDHRCATL-UHFFFAOYSA-N 0.000 description 1
WXSURELOKDGQNF-UHFFFAOYSA-N n-methyl-2,2-diphenylethanamine Chemical compound C=1C=CC=CC=1C(CNC)C1=CC=CC=C1 WXSURELOKDGQNF-UHFFFAOYSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229940080818 propionamide Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
LLVQEXSQFBTIRD-UHFFFAOYSA-M sodium;2,3,4-trihydroxy-4-oxobutanoate;hydrate Chemical compound O.[Na+].OC(=O)C(O)C(O)C([O-])=O LLVQEXSQFBTIRD-UHFFFAOYSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
TYSZETYVESRFNT-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylamino]carbamate Chemical compound CC(C)(C)OC(=O)NNC(=O)OC(C)(C)C TYSZETYVESRFNT-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
238000001665 trituration Methods 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
208000016261 weight loss Diseases 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Rheumatology (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)

NO20025405A 2000-05-12 2002-11-11 2-acetamidoacetamidderivater, anvendelse av slike forbindelser til fremstilling av preparater for behandling av sykdommer samt preparater omfattende slike forbindelser NO324693B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20378400P	2000-05-12	2000-05-12
US20521300P	2000-05-18	2000-05-18
PCT/US2001/015027 WO2001087849A2 (en)	2000-05-12	2001-05-10	Modulators of tnf- alpha signaling

Publications (3)

Publication Number	Publication Date
NO20025405D0 NO20025405D0 (no)	2002-11-11
NO20025405L NO20025405L (no)	2003-01-09
NO324693B1 true NO324693B1 (no)	2007-12-03

Family

ID=26898898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20025405A NO324693B1 (no)	2000-05-12	2002-11-11	2-acetamidoacetamidderivater, anvendelse av slike forbindelser til fremstilling av preparater for behandling av sykdommer samt preparater omfattende slike forbindelser

Country Status (13)

Country	Link
US (5)	US6969728B2 (ja)
EP (1)	EP1294699B1 (ja)
JP (3)	JP4960565B2 (ja)
KR (1)	KR100840816B1 (ja)
CN (1)	CN100494182C (ja)
AU (2)	AU2001259691B2 (ja)
BR (1)	BR0111158A (ja)
CA (3)	CA2876779A1 (ja)
HK (1)	HK1051186A1 (ja)
IL (2)	IL152450A0 (ja)
MX (1)	MXPA02010993A (ja)
NO (1)	NO324693B1 (ja)
WO (1)	WO2001087849A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1294699B1 (en)	2000-05-12	2016-04-13	Genzyme Corporation	Modulators of tnf- alpha signalling
DE10108481A1 (de) *	2001-02-22	2002-10-24	Bayer Ag	Pyridylpyrimidine
PL216985B1 (pl) *	2001-04-10	2014-06-30	Pfizer	Pochodne pirazolu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowania
CA2478183C (en) *	2002-03-12	2010-02-16	Merck & Co. Inc.	Substituted amides
JP4914008B2 (ja) *	2002-11-21	2012-04-11	ジェンザイム・コーポレーション	免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
PT1567138E (pt) *	2002-11-21	2011-04-11	Genzyme Corp	Utilização de derivados de diamida para inibição de rejeição crónica de transplante
WO2004056769A2 (en) *	2002-12-20	2004-07-08	Ciba Specialty Chemicals Holding Inc.	Synthesis of amines and intermediates for the synthesis thereof
US20060228305A1 (en) *	2003-02-11	2006-10-12	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
US7977366B2 (en) *	2003-10-14	2011-07-12	Cornell Research Foundation, Inc.	Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
EP1765347A4 (en) *	2004-06-04	2008-10-01	Univ California	COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE
US20100222393A1 (en) *	2005-12-30	2010-09-02	Naresh Kumar	Muscarinic receptor antagonists
RU2503463C2 (ru) *	2006-07-03	2014-01-10	Чарльз Дэвид ЭДЕЙР	Композиция для модулирования экспрессии молекул клеточной адгезии
CA2675511A1 (en)	2006-10-10	2008-04-17	Amgen Inc.	N-aryl pyrazole compounds for use against diabetes
US20110118274A1 (en) *	2007-08-23	2011-05-19	Cornell Research Foundation, Inc.	Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2009073146A2 (en) *	2007-11-29	2009-06-11	Celgene Corporation	Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
WO2013142376A1 (en) *	2012-03-19	2013-09-26	Aposignal Bioscience Llc	Composition and methods for cell modulation
UY36034A (es)	2014-03-18	2015-09-30	Astrazeneca Ab	Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE372326C (de)	1922-04-22	1923-03-26	Adam Thierauf	Turbinenanlage
DE748704C (de)	1938-02-26	1944-11-08		Einrichtung zum federnden Begrenzen des Laengsspiels der in Gleitlagern laufenden Ankerwelle von Elektrokleinmotoren
US3935263A (en) *	1971-12-10	1976-01-27	Eastman Kodak Company	Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same
CA996119A (en)	1971-12-10	1976-08-31	Eastman Kodak Company	Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same
DE2937698A1 (de) *	1979-09-18	1981-04-02	A. Nattermann & Cie GmbH, 5000 Köln	N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
US5672347A (en) *	1984-07-05	1997-09-30	Genentech, Inc.	Tumor necrosis factor antagonists and their use
EP0246749A3 (en)	1986-05-17	1988-08-31	AgrEvo UK Limited	Triazole herbicides
JPH01101456A (ja) *	1987-10-15	1989-04-19	Honda Electron Co Ltd	超音波顕微鏡装置
DE3825867A1 (de)	1988-03-04	1989-09-14	Bayer Ag	Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide
DE3813886A1 (de)	1988-04-20	1989-11-02	Schering Ag	1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
US4944796A (en) *	1988-11-14	1990-07-31	Ici Americas Inc.	Certain 2-(disubstituted amino) acetanilide herbicides
DE3841086A1 (de)	1988-12-07	1990-06-21	Bayer Ag	Sulfonylaminoazine, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) *	1989-04-20	1991-03-05	Richard Finbar Murphy	Novel C-terminal gastrin antagonists
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE3928605A1 (de)	1989-08-30	1991-03-07	Bayer Ag	Substituierte sulfonylaminoazole
JPH0686378B2 (ja) *	1990-05-31	1994-11-02	田辺製薬株式会社	免疫調節剤
US5958413A (en) *	1990-11-01	1999-09-28	Celltech Limited	Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) *	1990-11-30	2002-07-16	Fred Hutchinson Cancer Research Center	Use of xanthines as immunosuppressants and to inhibit allograft reactions
WO1992017456A1 (en) *	1991-03-26	1992-10-15	Fujisawa Pharmaceutical Co., Ltd.	Amino acid derivative and salt thereof
EP0520573A1 (en)	1991-06-27	1992-12-30	Glaxo Inc.	Cyclic imide derivatives
AU665238B2 (en)	1992-02-28	1995-12-21	Zenyaku Kogyo Kabushiki Kaisha	S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US5861382A (en) *	1992-05-01	1999-01-19	Yeda Research And Development Co. Ltd.	Methods for regulation of active TNF-α
WO1995009652A1 (en)	1993-10-06	1995-04-13	The Kennedy Institute For Rheumatology	Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) *	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en)	1992-10-08	2009-05-05	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
US6645493B1 (en) *	1993-05-17	2003-11-11	The Picower Institute For Medical Research	Composition containing anti-MIF antibody
DE4337600A1 (de) *	1993-11-01	1995-05-04	Diagnostikforschung Inst	N-Alkyl-Peptidchelatbildner, deren Metallkomplexe mit Radionukliden, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Zusammesetzungen
NZ278607A (en) *	1994-02-07	1999-05-28	Knoll Ag	Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430127A1 (de) *	1994-08-25	1996-03-14	Hoechst Ag	Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DE4430128A1 (de) *	1994-08-25	1996-02-29	Hoechst Ag	Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
US5932737A (en) *	1994-12-02	1999-08-03	Fujisawa Pharmaceutical Co., Ltd.	Peptide compounds for treatment of no-mediated diseases
US5632367A (en)	1995-01-23	1997-05-27	Mars, Incorporated	Validation housing for a bill validator made by a two shot molding process
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
FR2730411B1 (fr) *	1995-02-14	1997-03-28	Centre Nat Rech Scient	Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
DK0766745T3 (da)	1995-04-08	2002-11-25	Lg Chemical Ltd	Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
CA2217857A1 (en)	1995-05-10	1996-11-14	Darwin Discovery Limited	Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
SE510202C2 (sv)	1995-05-19	1999-04-26	Stroemsholmen Ab	Anordning vid ett hydraulsystem
US5654312A (en) *	1995-06-07	1997-08-05	Andrulis Pharmaceuticals	Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
DE69532557T2 (de) *	1995-07-20	2004-12-23	Cellena (Cell Engineering) Ag	Zubereitung enthaltend Glykane übereinstimmend mit Transferrin Glykaner als aktives Prinzip für die Induktion der Immuntoleranz gegen Antigene
IL115245A (en) *	1995-09-11	2002-12-01	Yissum Res Dev Co	Tumor necrosis factor inhibiting pharmaceuticals
ES2172690T3 (es)	1995-11-22	2002-10-01	Darwin Discovery Ltd	Compuestos de mercaptoalquilpeptidil con un sustituyente de imidazol y su utilizacion como inhibidores de metaloproteinasas de matriz (mmp) y/o del factor de necrosis tumoral (tnf).
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
AU2521597A (en) *	1996-04-12	1997-11-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyramidine derivatives
US6211160B1 (en) *	1996-09-06	2001-04-03	The Trustees Of The University Of Pennsylvania	Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
WO1998024782A2 (en) *	1996-12-05	1998-06-11	Amgen Inc.	Substituted pyrimidine compounds and their use
JP2001513754A (ja) *	1996-12-06	2001-09-04	アムジェンインコーポレイテッド	Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
JP2001508450A (ja)	1997-01-10	2001-06-26	バイオジェンインコーポレイテッド	抗ｃｄ４０ｌ化合物の治療学的投与の方法
US6294170B1 (en) *	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
WO1998039026A2 (en)	1997-03-07	1998-09-11	Biogen, Inc.	Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) *	1997-04-15	1998-09-01	Immune Modulation, Inc.	Compositions and methods for immunosuppressing
US6506569B1 (en) *	1997-05-30	2003-01-14	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor TR10
GB9713732D0 (en) *	1997-06-27	1997-09-03	Pharmacia & Upjohn Spa	Substituted triazinic compounds
EP1002078A1 (en)	1997-07-31	2000-05-24	Chiron Corporation	Method enabling readministration of aav vector via immunosuppresion of host
US6503184B1 (en) *	1997-10-21	2003-01-07	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6022884A (en) *	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
US6407218B1 (en) *	1997-11-10	2002-06-18	Cytimmune Sciences, Inc.	Method and compositions for enhancing immune response and for the production of in vitro mabs
EP1036066B1 (en)	1997-12-03	2007-04-18	Mid-America Commercialization Corporation	Substituted pyrimidine and pyridine herbicides
AU3368899A (en) *	1998-03-30	1999-10-18	Cambridge Neuroscience, Inc.	Protein-carbohydrate binding antagonists
CA2329065A1 (en) *	1998-05-05	1999-11-11	Francisco Xavier Talamas	Pyrazole derivatives as p-38 map kinase inhibitors
FR2780891A1 (fr)	1998-07-10	2000-01-14	Univ Paris Curie	Echange de lymphocytes t
AU6476599A (en) *	1998-11-03	2000-05-22	Novartis Ag	Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
US6359061B1 (en)	1999-03-19	2002-03-19	Isis Pharmaceuticals, Inc.	Amide compound libraries
WO2000059874A1 (en) *	1999-04-02	2000-10-12	Du Pont Pharmaceuticals Company	NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
US6365617B1 (en)	1999-06-29	2002-04-02	Ortho-Mcneil Pharmaceutical, Inc.	Indole and indazole urea-peptoids as thrombin receptor antagonists
US6204245B1 (en) *	1999-09-17	2001-03-20	The Regents Of The University Of California	Treatment of narcolepsy with immunosuppressants
AU1590201A (en)	1999-11-09	2001-06-06	Chiron Corporation	Compositions and methods for treating autoimmune diseases and transplant rejections
AU3006401A (en)	1999-12-07	2001-06-18	Novartis Ag	Vla-4 integrin antagonists
DE10019755A1 (de)	2000-04-20	2001-11-08	Bayer Ag	Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
EP1294699B1 (en) *	2000-05-12	2016-04-13	Genzyme Corporation	Modulators of tnf- alpha signalling
KR20030001551A (ko) *	2000-05-22	2003-01-06	레오 파마 에이/에스	ＩＬ-1β 및 ＴＮＦ-α 억제제로서의 벤조페논
US20040072728A1 (en) *	2002-06-26	2004-04-15	Fawwaz Rashid A.	Use of streptavidin to inhibit transplant rejection
JP4914008B2 (ja) *	2002-11-21	2012-04-11	ジェンザイム・コーポレーション	免疫寛容を誘導するためのジアミド誘導体と免疫抑制剤との組み合わせ
PT1567138E (pt) *	2002-11-21	2011-04-11	Genzyme Corp	Utilização de derivados de diamida para inibição de rejeição crónica de transplante

2001
- 2001-05-10 EP EP01933253.5A patent/EP1294699B1/en not_active Expired - Lifetime
- 2001-05-10 MX MXPA02010993A patent/MXPA02010993A/es active IP Right Grant
- 2001-05-10 CA CA2876779A patent/CA2876779A1/en not_active Abandoned
- 2001-05-10 US US09/852,965 patent/US6969728B2/en not_active Expired - Lifetime
- 2001-05-10 CN CNB018127363A patent/CN100494182C/zh not_active Expired - Fee Related
- 2001-05-10 AU AU2001259691A patent/AU2001259691B2/en not_active Ceased
- 2001-05-10 CA CA2408408A patent/CA2408408C/en not_active Expired - Lifetime
- 2001-05-10 JP JP2001584245A patent/JP4960565B2/ja not_active Expired - Lifetime
- 2001-05-10 KR KR1020027015152A patent/KR100840816B1/ko active IP Right Grant
- 2001-05-10 CA CA 2781858 patent/CA2781858C/en not_active Expired - Lifetime
- 2001-05-10 BR BR0111158A patent/BR0111158A/pt not_active Application Discontinuation
- 2001-05-10 IL IL15245001A patent/IL152450A0/xx unknown
- 2001-05-10 WO PCT/US2001/015027 patent/WO2001087849A2/en active Application Filing
- 2001-05-10 AU AU5969101A patent/AU5969101A/xx active Pending
2002
- 2002-10-24 IL IL15245002A patent/IL152450A/en active IP Right Grant
- 2002-11-11 NO NO20025405A patent/NO324693B1/no not_active IP Right Cessation
2003
- 2003-05-12 HK HK03103293.5A patent/HK1051186A1/zh not_active IP Right Cessation
2004
- 2004-03-10 US US10/797,244 patent/US7034031B2/en not_active Expired - Lifetime
2005
- 2005-12-01 US US11/292,325 patent/US8518999B2/en not_active Expired - Lifetime
2011
- 2011-10-14 JP JP2011226847A patent/JP5529827B2/ja not_active Expired - Fee Related
2013
- 2013-07-19 US US13/946,389 patent/US8921547B2/en not_active Expired - Fee Related
2014
- 2014-03-06 JP JP2014043411A patent/JP5754040B2/ja not_active Expired - Fee Related
- 2014-11-25 US US14/553,313 patent/US9579325B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2781858A1 (en)	2001-11-22
US20150126512A1 (en)	2015-05-07
US20060173010A1 (en)	2006-08-03
KR20030015242A (ko)	2003-02-20
JP2014129406A (ja)	2014-07-10
US6969728B2 (en)	2005-11-29
WO2001087849A3 (en)	2002-06-06
CA2408408C (en)	2013-07-09
CA2781858C (en)	2015-03-31
CN100494182C (zh)	2009-06-03
NO20025405D0 (no)	2002-11-11
US20130310388A1 (en)	2013-11-21
US8518999B2 (en)	2013-08-27
US20020119988A1 (en)	2002-08-29
JP5529827B2 (ja)	2014-06-25
NO20025405L (no)	2003-01-09
JP5754040B2 (ja)	2015-07-22
CA2876779A1 (en)	2001-11-22
BR0111158A (pt)	2004-04-06
EP1294699A2 (en)	2003-03-26
EP1294699B1 (en)	2016-04-13
US9579325B2 (en)	2017-02-28
JP2003533515A (ja)	2003-11-11
IL152450A0 (en)	2003-05-29
WO2001087849A2 (en)	2001-11-22
US8921547B2 (en)	2014-12-30
CA2408408A1 (en)	2001-11-22
AU5969101A (en)	2001-11-26
MXPA02010993A (es)	2003-03-10
US7034031B2 (en)	2006-04-25
KR100840816B1 (ko)	2008-06-23
CN1441787A (zh)	2003-09-10
US20040171617A1 (en)	2004-09-02
JP4960565B2 (ja)	2012-06-27
JP2012051917A (ja)	2012-03-15
IL152450A (en)	2009-09-01
HK1051186A1 (zh)	2003-07-25
AU2001259691B2 (en)	2006-02-16

Legal Events

Date	Code	Title	Description
2021-01-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US9579325B2 (en)	2017-02-28	Modulators of TNF-α signaling
AU2021250993B2 (en)	2024-02-22	Aryl receptor modulators and methods of making and using the same
RU2351596C2 (ru)	2009-04-10	Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида и их применение в терапии
DE60027011T2 (de)	2006-12-07	Harnstoffderivate als CCR-3 Rezeptor-Inhibitoren
ZA200603181B (en)	2008-01-30	3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
TW200306830A (en)	2003-12-01	N-[phenyl (piperidin-2-yl) methyl] benzamide derivatives, their preparation and their application in therapy
CN111344290A (zh)	2020-06-26	作为Wee1抑制剂的大环类化合物及其应用
AU2001259691A1 (en)	2002-02-14	Modulators of TNF-alpha signaling
JP2007523179A (ja)	2007-08-16	アセチレン系ピペラジン化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用
CN110248935A (zh)	2019-09-17	用于治疗疼痛和疼痛相关病症的含氮二环衍生物
TW201516044A (zh)	2015-05-01	１，７－萘啶衍生物
RU2324685C2 (ru)	2008-05-20	Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
EA027882B1 (ru)	2017-09-29	Этинильные производные в качестве антагонистов метаботропного глутаматного рецептора
US11905244B2 (en)	2024-02-20	Chemical modulators of store-operated calcium channels and their therapeutic applications
RU2299882C2 (ru)	2007-05-27	Бензотиофены в качестве модуляторов аденозинового рецептора
CN100391935C (zh)	2008-06-04	环戊基衍生物
CN117624126A (zh)	2024-03-01	选择性酪氨酸激酶2（tyk2）抑制剂化合物、合成方法及用途
US20200087264A1 (en)	2020-03-19	Novel selective ligand for dopamine d3 receptor, preparation method therefor, and pharmaceutical application thereof